Harvard spinout TScan Therapeutics has successfully listed on the Nasdaq Global Market.

TScan Therapeutics, the US-based cancer immunotherapy developer spun out of Harvard University, secured $100m in its initial public offering on Friday. The company issued almost 6.7 million shares on the Nasdaq Global Market priced at $15 each, having set a range of $15 to $17 for 6.3 million shares. It is listed under the ticker…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.